Pharmacyclics (PCYC) Inactive 10-Q2013 Q1 Quarterly report

Filed: 7 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AACR, adenocarcinoma, adjacent, Anderson, antibody, apparent, assigned, Atlanta, biomarker, bleeding, book, borrowing, Boston, breach, breaching, Breakthrough, burden, capacity, central, characterized, chemoimmunotherapy, chlorambucil, chromosome, clarified, Clarifying, conventional, count, counter, CR, creation, CRs, cure, cytopenia, Czech, Dana, debarment, deducting, del, detail, detrimental, dexamethasone, driven, driver, durable, elapsed, emergence, emergent, entirety, expedite, explode, exploding, explore, explosion, Farber, faster, FDCA, FL, flammable, footage, fourth, GAAP, gastrointestinal, gave, GCB, Heart, Hodgkin, ICML, ignite, igniting, incapacitate, Index, infection, insignificant, insomnia, insufficient, intolerability, lenalidomide, lending, lt, Lugano, lymphoplasmacytic, macroglobulinemia, medicinal, metabolism, mice, mitigate, mo, molecular, monoclonal, monotherapy, multiply, multitude, mutation, neutropenia, orphan, outpatient, owner, ownership, Oxley, PaCa, pain, paraprotein, pathophysiology, pension, percent, platelet, pneumonia, poster, PR, Prague, prednisone, predominantly, presumption, pretreated, Prognostic, proliferation, prothrombin, PRs, published, qualification, radiological, Rai, rash, RAY, reinstated, Relief, repayment, Republic, repurchase, retaliation, retroactive, revert, screening, SD, SHINE, SPA, SPARK, speed, split, stipulated, subset, synergistic, Taxpayer, tract, transition, Treon, unaffected, uncommon, uncured, underwritten, uptake, Waldenstrom, white, WM, xenograft

Removed: assist, CEO, device, distinct, Division, duggan, earned, enrolling, GC, genetically, recommended, record, robert, September, spending, travel

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PCYC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Pharmacyclics, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, Robert W. Duggan, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ ROBERT W. DUGGAN

Robert W. Duggan

Chairman of the Board and Chief Executive Officer

(Principal Executive Officer)

May 7, 2013

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Pharmacyclics, Inc, a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, Joshua T. Brumm, Principal Financial Officer of the Company, certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ JOSHUA T. BRUMM

Joshua T. Brumm

Executive Vice President, Finance

(Principal Financial Officer)

May 7, 2013